Background
QDENGA Vaccine, also known as TAK-003, is a vaccine developed by Takeda for the prevention of dengue. Dengue is a mosquito-borne viral disease transmitted mainly by Aedes aegypti mosquitoes and is caused by four related dengue virus serotypes:
- DENV-1
- DENV-2
- DENV-3
- DENV-4
Infection with one serotype generally provides long-term immunity only against that particular serotype. A later infection with a different serotype may increase the risk of severe dengue in some individuals. This makes the development of an effective dengue vaccine scientifically challenging.
In July 2026, the Central Drugs Standard Control Organisation approved QDENGA as India’s first dengue vaccine. It was authorised for individuals between 4 and 60 years of age, subject to the conditions specified by the Indian regulator.
Nature and Working of the Vaccine
QDENGA is a live-attenuated tetravalent vaccine. “Live attenuated” means that it contains weakened forms of the virus that can stimulate an immune response without ordinarily causing dengue disease in a healthy recipient.
It is called tetravalent because it is designed to provide protection against all four dengue virus serotypes.
The vaccine uses an attenuated DENV-2 virus as its genetic backbone. Genes responsible for important surface proteins from DENV-1, DENV-3 and DENV-4 are inserted into this backbone through recombinant DNA technology. The immune system is therefore exposed to antigens representing all four serotypes and develops antibodies and cellular immune responses against them.
Unlike the earlier dengue vaccine Dengvaxia, QDENGA can be administered without routinely testing whether a person has previously suffered from dengue. This simplifies its use in public-health programmes and areas where reliable pre-vaccination testing is difficult.
Administration, Eligibility and Precautions
The vaccination course consists of two doses, administered by subcutaneous injection with a gap of three months between the doses. Each dose is generally given under the skin of the upper arm.
The regulatory age range may differ across countries. The European Union has authorised it for individuals aged four years and above, while India has approved it for those aged 4–60 years. WHO’s public-health recommendation is narrower: it recommends programmatic use mainly among children aged 6–16 years in areas with a high dengue burden and intense transmission.
As it is a live vaccine, it is generally not suitable for:
- pregnant women;
- individuals with severe immunodeficiency;
- persons receiving strong immunosuppressive treatment;
- individuals who have experienced a severe allergic reaction to an earlier dose or any component of the vaccine.
Vaccination may need to be postponed during an acute illness with high fever. Medical advice is necessary because eligibility depends on the recipient’s age, health, immune status and applicable national guidelines.
Common adverse effects may include pain or redness at the injection site, headache, muscle pain, tiredness, fever and general discomfort. These reactions are generally mild and temporary.
Effectiveness and Limitations
Clinical trials showed that QDENGA reduces the risk of virologically confirmed dengue and offers stronger protection against hospitalisation and severe disease. Follow-up data reported vaccine efficacy of approximately 61% against virologically confirmed dengue over four and a half years, with higher protection against dengue-related hospitalisation.
However, vaccine performance is not identical against every serotype or in every population. Evidence has been strongest against DENV-2, while protection against some other serotypes has varied according to whether a recipient had previously been infected with dengue.
WHO does not currently recommend routine programme use in children below six years because of lower observed efficacy and lower dengue seropositivity in this age group. It also recommends concentrating vaccination in settings where dengue transmission and disease burden are high, rather than introducing it uniformly in areas with low transmission.
The vaccine does not provide complete protection. A vaccinated person can still become infected and must continue preventive measures such as:
- eliminating stagnant water;
- controlling mosquito breeding;
- using repellents and protective clothing;
- maintaining surveillance and early diagnosis;
- obtaining timely treatment for warning symptoms.
QDENGA is therefore an additional preventive instrument and not a substitute for mosquito control or public-health surveillance.
Public-Health Importance
Dengue creates a substantial health burden in tropical and subtropical countries. Rapid urbanisation, poor water management, high population density, increased travel and climate-related changes in mosquito distribution have contributed to its expansion.
QDENGA is important because it can potentially:
- reduce symptomatic dengue infections;
- lower hospital admissions;
- reduce the risk of severe dengue;
- ease pressure on hospitals during seasonal outbreaks;
- reduce the economic burden on families and health systems;
- complement vector-control programmes.
WHO prequalified the vaccine in May 2024, enabling United Nations agencies and eligible international organisations to procure it for public-health programmes. WHO recommends prioritising children aged 6–16 years in high-transmission areas because this age group is likely to gain the greatest population-level benefit.
India’s approval is significant because the country experiences recurrent dengue outbreaks across several states and urban centres. However, regulatory approval does not automatically mean universal inclusion in the national immunisation programme. Decisions regarding large-scale introduction require assessment of disease burden, cost-effectiveness, supply, safety surveillance and identification of high-risk regions.
Conclusion
QDENGA represents an important advance in dengue prevention because it targets all four dengue virus serotypes and does not ordinarily require prior infection testing. Its greatest value is likely to arise when vaccination is combined with mosquito control, disease surveillance, community participation and timely clinical management.
Here is the cleaned version without source links.
